Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01076348 · ClinicalTrials.gov registry record

Model 4965 Post-Approval Study

A clinical trial of Heart Failure and Bradycardia, sponsored by Medtronic.

Completed
Registry status
73
Enrollment target
20
Study locations

NCT01076348: Completed study of Heart Failure and Bradycardia, sponsored by Medtronic.

NCT01076348 is a study of Heart Failure and Bradycardia that has completed, run by Medtronic. The registered enrollment target is 73 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01076348, a study of Heart Failure and Bradycardia, has completed, sponsored by Medtronic.

COMPLETED
Registry status
73 participants
Enrollment target
20
Study locations

Study Summary

Safety and effectiveness will be summarized for the model 4965 lead. This study was conducted within Medtronic's System Longevity Study (SLS).

Primary Outcome

A 4965 lead-related complication is an adverse event requiring invasive intervention to resolve. The complication-free rate is based on the number of leads analyzed.

Study Locations (20)

California

  • - Bakersfield
  • - Chula Vista
  • - Downey
  • - East Palo Alto
  • - Los Angeles
  • - Salinas
  • - Torrance
  • - Van Nuys

Florida

  • - Clearwater
  • - Jacksonville
  • - Melbourne
  • - Ocala

Arizona

  • - Phoenix
  • - Scottsdale

Colorado

  • - Colorado Springs
  • - Denver

Alabama

  • - Birmingham

Alaska

  • - Anchorage

Arkansas

  • - Little Rock

District of Columbia

  • - Washington D.C.

Trial Details

FieldValue
Enrollment Target 73 participants
Start Date 1996-09
Est. Completion 2011-04
Medtronic

30 total trials

What the finished NCT01076348 record still lists

NCT01076348 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (96% lower).

The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 0 interventions.

NCT01076348 names 20 study sites across 8 states, led by California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT01076348 about?

NCT01076348 is a clinical study titled "Model 4965 Post-Approval Study". Safety and effectiveness will be summarized for the model 4965 lead. This study was conducted within Medtronic's System Longevity Study (SLS).

What is the current status of trial NCT01076348?

This trial is currently completed. The enrollment target is 73 participants. The study started on 1996-09. Estimated completion is 2011-04.

What conditions does trial NCT01076348 study?

This clinical trial studies the following conditions: Heart Failure, Bradycardia, Arrhythmia, Pacing.

Who is sponsoring clinical trial NCT01076348?

This trial is sponsored by Medtronic, which has 30 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01076348 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01076348's enrollment target sits among peer trials

73 239th of 397 higher than 159 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03661307 · 73 participants · Phase 1

    Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

  • NCT05386108 · 73 participants · Phase 1

    Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

  • NCT05961592 · 73 participants · Phase 1

    R-2487 in Patients With Rheumatoid Arthritis

  • NCT06150664 · 73 participants · Phase 1

    A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01076348, the US trial registry maintained by the National Library of Medicine. NCT01076348 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.